Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis
Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resista...
Ausführliche Beschreibung
Autor*in: |
Naomee Shareef [verfasserIn] Ahmed Abu Saleh [verfasserIn] Abu Naser Ibne Sattar [verfasserIn] Shaheda Anwar [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Bangabandhu Sheikh Mujib Medical University Journal - Bangabandhu Sheikh Mujib Medical University, 2017, 16(2023), 3 |
---|---|
Übergeordnetes Werk: |
volume:16 ; year:2023 ; number:3 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.3329/bsmmuj.v16i3.64496 |
---|
Katalog-ID: |
DOAJ09191289X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ09191289X | ||
003 | DE-627 | ||
005 | 20240414194212.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240412s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3329/bsmmuj.v16i3.64496 |2 doi | |
035 | |a (DE-627)DOAJ09191289X | ||
035 | |a (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Naomee Shareef |e verfasserin |4 aut | |
245 | 1 | 0 | |a Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 | ||
650 | 4 | |a MDR-TB, RIF resistance, INH resistance, katG, inhA | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Ahmed Abu Saleh |e verfasserin |4 aut | |
700 | 0 | |a Abu Naser Ibne Sattar |e verfasserin |4 aut | |
700 | 0 | |a Shaheda Anwar |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Bangabandhu Sheikh Mujib Medical University Journal |d Bangabandhu Sheikh Mujib Medical University, 2017 |g 16(2023), 3 |w (DE-627)635605961 |w (DE-600)2573885-9 |x 22247750 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2023 |g number:3 |
856 | 4 | 0 | |u https://doi.org/10.3329/bsmmuj.v16i3.64496 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e |z kostenfrei |
856 | 4 | 0 | |u https://banglajol.info/index.php/BSMMUJ/article/view/64496 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2074-2908 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2224-7750 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 16 |j 2023 |e 3 |
author_variant |
n s ns a a s aas a n i s anis s a sa |
---|---|
matchkey_str |
article:22247750:2023----::snairssacpoieniapcneitnmcbc |
hierarchy_sort_str |
2023 |
publishDate |
2023 |
allfields |
10.3329/bsmmuj.v16i3.64496 doi (DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e DE-627 ger DE-627 rakwb eng Naomee Shareef verfasserin aut Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R Ahmed Abu Saleh verfasserin aut Abu Naser Ibne Sattar verfasserin aut Shaheda Anwar verfasserin aut In Bangabandhu Sheikh Mujib Medical University Journal Bangabandhu Sheikh Mujib Medical University, 2017 16(2023), 3 (DE-627)635605961 (DE-600)2573885-9 22247750 nnns volume:16 year:2023 number:3 https://doi.org/10.3329/bsmmuj.v16i3.64496 kostenfrei https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e kostenfrei https://banglajol.info/index.php/BSMMUJ/article/view/64496 kostenfrei https://doaj.org/toc/2074-2908 Journal toc kostenfrei https://doaj.org/toc/2224-7750 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 3 |
spelling |
10.3329/bsmmuj.v16i3.64496 doi (DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e DE-627 ger DE-627 rakwb eng Naomee Shareef verfasserin aut Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R Ahmed Abu Saleh verfasserin aut Abu Naser Ibne Sattar verfasserin aut Shaheda Anwar verfasserin aut In Bangabandhu Sheikh Mujib Medical University Journal Bangabandhu Sheikh Mujib Medical University, 2017 16(2023), 3 (DE-627)635605961 (DE-600)2573885-9 22247750 nnns volume:16 year:2023 number:3 https://doi.org/10.3329/bsmmuj.v16i3.64496 kostenfrei https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e kostenfrei https://banglajol.info/index.php/BSMMUJ/article/view/64496 kostenfrei https://doaj.org/toc/2074-2908 Journal toc kostenfrei https://doaj.org/toc/2224-7750 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 3 |
allfields_unstemmed |
10.3329/bsmmuj.v16i3.64496 doi (DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e DE-627 ger DE-627 rakwb eng Naomee Shareef verfasserin aut Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R Ahmed Abu Saleh verfasserin aut Abu Naser Ibne Sattar verfasserin aut Shaheda Anwar verfasserin aut In Bangabandhu Sheikh Mujib Medical University Journal Bangabandhu Sheikh Mujib Medical University, 2017 16(2023), 3 (DE-627)635605961 (DE-600)2573885-9 22247750 nnns volume:16 year:2023 number:3 https://doi.org/10.3329/bsmmuj.v16i3.64496 kostenfrei https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e kostenfrei https://banglajol.info/index.php/BSMMUJ/article/view/64496 kostenfrei https://doaj.org/toc/2074-2908 Journal toc kostenfrei https://doaj.org/toc/2224-7750 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 3 |
allfieldsGer |
10.3329/bsmmuj.v16i3.64496 doi (DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e DE-627 ger DE-627 rakwb eng Naomee Shareef verfasserin aut Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R Ahmed Abu Saleh verfasserin aut Abu Naser Ibne Sattar verfasserin aut Shaheda Anwar verfasserin aut In Bangabandhu Sheikh Mujib Medical University Journal Bangabandhu Sheikh Mujib Medical University, 2017 16(2023), 3 (DE-627)635605961 (DE-600)2573885-9 22247750 nnns volume:16 year:2023 number:3 https://doi.org/10.3329/bsmmuj.v16i3.64496 kostenfrei https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e kostenfrei https://banglajol.info/index.php/BSMMUJ/article/view/64496 kostenfrei https://doaj.org/toc/2074-2908 Journal toc kostenfrei https://doaj.org/toc/2224-7750 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 3 |
allfieldsSound |
10.3329/bsmmuj.v16i3.64496 doi (DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e DE-627 ger DE-627 rakwb eng Naomee Shareef verfasserin aut Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R Ahmed Abu Saleh verfasserin aut Abu Naser Ibne Sattar verfasserin aut Shaheda Anwar verfasserin aut In Bangabandhu Sheikh Mujib Medical University Journal Bangabandhu Sheikh Mujib Medical University, 2017 16(2023), 3 (DE-627)635605961 (DE-600)2573885-9 22247750 nnns volume:16 year:2023 number:3 https://doi.org/10.3329/bsmmuj.v16i3.64496 kostenfrei https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e kostenfrei https://banglajol.info/index.php/BSMMUJ/article/view/64496 kostenfrei https://doaj.org/toc/2074-2908 Journal toc kostenfrei https://doaj.org/toc/2224-7750 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 3 |
language |
English |
source |
In Bangabandhu Sheikh Mujib Medical University Journal 16(2023), 3 volume:16 year:2023 number:3 |
sourceStr |
In Bangabandhu Sheikh Mujib Medical University Journal 16(2023), 3 volume:16 year:2023 number:3 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
MDR-TB, RIF resistance, INH resistance, katG, inhA Medicine R |
isfreeaccess_bool |
true |
container_title |
Bangabandhu Sheikh Mujib Medical University Journal |
authorswithroles_txt_mv |
Naomee Shareef @@aut@@ Ahmed Abu Saleh @@aut@@ Abu Naser Ibne Sattar @@aut@@ Shaheda Anwar @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
635605961 |
id |
DOAJ09191289X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09191289X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414194212.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3329/bsmmuj.v16i3.64496</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09191289X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Naomee Shareef</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MDR-TB, RIF resistance, INH resistance, katG, inhA</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed Abu Saleh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abu Naser Ibne Sattar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shaheda Anwar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Bangabandhu Sheikh Mujib Medical University Journal</subfield><subfield code="d">Bangabandhu Sheikh Mujib Medical University, 2017</subfield><subfield code="g">16(2023), 3</subfield><subfield code="w">(DE-627)635605961</subfield><subfield code="w">(DE-600)2573885-9</subfield><subfield code="x">22247750</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3329/bsmmuj.v16i3.64496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://banglajol.info/index.php/BSMMUJ/article/view/64496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2074-2908</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2224-7750</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
author |
Naomee Shareef |
spellingShingle |
Naomee Shareef misc MDR-TB, RIF resistance, INH resistance, katG, inhA misc Medicine misc R Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
authorStr |
Naomee Shareef |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)635605961 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
22247750 |
topic_title |
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis MDR-TB, RIF resistance, INH resistance, katG, inhA |
topic |
misc MDR-TB, RIF resistance, INH resistance, katG, inhA misc Medicine misc R |
topic_unstemmed |
misc MDR-TB, RIF resistance, INH resistance, katG, inhA misc Medicine misc R |
topic_browse |
misc MDR-TB, RIF resistance, INH resistance, katG, inhA misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Bangabandhu Sheikh Mujib Medical University Journal |
hierarchy_parent_id |
635605961 |
hierarchy_top_title |
Bangabandhu Sheikh Mujib Medical University Journal |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)635605961 (DE-600)2573885-9 |
title |
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
ctrlnum |
(DE-627)DOAJ09191289X (DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e |
title_full |
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
author_sort |
Naomee Shareef |
journal |
Bangabandhu Sheikh Mujib Medical University Journal |
journalStr |
Bangabandhu Sheikh Mujib Medical University Journal |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Naomee Shareef Ahmed Abu Saleh Abu Naser Ibne Sattar Shaheda Anwar |
container_volume |
16 |
format_se |
Elektronische Aufsätze |
author-letter |
Naomee Shareef |
doi_str_mv |
10.3329/bsmmuj.v16i3.64496 |
author2-role |
verfasserin |
title_sort |
isoniazid resistance profile in rifampicin resistant mycobacterium tuberculosis |
title_auth |
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
abstract |
Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 |
abstractGer |
Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 |
abstract_unstemmed |
Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis |
url |
https://doi.org/10.3329/bsmmuj.v16i3.64496 https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e https://banglajol.info/index.php/BSMMUJ/article/view/64496 https://doaj.org/toc/2074-2908 https://doaj.org/toc/2224-7750 |
remote_bool |
true |
author2 |
Ahmed Abu Saleh Abu Naser Ibne Sattar Shaheda Anwar |
author2Str |
Ahmed Abu Saleh Abu Naser Ibne Sattar Shaheda Anwar |
ppnlink |
635605961 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3329/bsmmuj.v16i3.64496 |
up_date |
2024-07-03T22:59:25.671Z |
_version_ |
1803600596222083072 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09191289X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414194212.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3329/bsmmuj.v16i3.64496</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09191289X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ668c66c68ec44d1b9f8f36edba85b88e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Naomee Shareef</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB. Methods: In this cross-sectional study, from March 2021 to February 2022, 53 RIF-resistant MTB isolates in sputum samples detected by Xpert-MTB RIF assay were enrolled. All samples were tested for mutation in katG (codon 315) and inhA promoter (-5, -8, -15 and -16) genes to detect INH resistance by real-time PCR. Statistical analysis was done using IBM SPSS (version 26). Results: Out of 53 RIF-resistant samples, 15.1% were sensitive to INH, and the rest had concomitant resistance to INH. The proportion of newly diagnosed and previously treated cases was nearly equal, and most of the previously treated cases (92.9%) received treatment regularly. INH-resistant cases were mostly previously treated (55.5%), whereas sensitive cases were mostly newly diagnosed (62.5%). KatG was found to be the prominent mutation, with or without in combination with inhA mutation. Conclusion: A considerable number of RIF-resistant isolates did not show concomitant resistance to INH. Most of the INH-resistant isolates were associated with katG mutation. Evaluation of INH resistance before using high-dose INH will help to avoid dose-dependent toxicity in MDR-TB patients. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(3): 160-166 </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MDR-TB, RIF resistance, INH resistance, katG, inhA</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed Abu Saleh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abu Naser Ibne Sattar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shaheda Anwar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Bangabandhu Sheikh Mujib Medical University Journal</subfield><subfield code="d">Bangabandhu Sheikh Mujib Medical University, 2017</subfield><subfield code="g">16(2023), 3</subfield><subfield code="w">(DE-627)635605961</subfield><subfield code="w">(DE-600)2573885-9</subfield><subfield code="x">22247750</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3329/bsmmuj.v16i3.64496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/668c66c68ec44d1b9f8f36edba85b88e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://banglajol.info/index.php/BSMMUJ/article/view/64496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2074-2908</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2224-7750</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
score |
7.4001083 |